Close Menu

NEW YORK (GenomeWeb) – Adaptive Biotechnologies plans to collaborate with Amgen to develop and commercialize Adaptive's next-generation sequencing-based immune profiling assay, ClonoSeq, to assess minimal residual disease in patients with acute lymphoblastic leukemia, Adaptive said today.

As part of the collaboration, the companies plan to collect MRD data in order to establish validated thresholds of residual disease that can predict patient outcomes in ALL.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Oct
27
Sponsored by
LGC SeraCare Life Sciences

This webinar brings together an expert panel of stakeholders in cancer diagnostics and clinical care who will discuss the promise and challenges of liquid biopsy technologies in cancer diagnosis, monitoring, and patient care management.